Carmen Sorina Martin1,2, Anca Elena Sirbu3,4, Minodora Andreea Betivoiu4, Suzana Florea5, Carmen Gabriela Barbu3,4, Simona Vasilica Fica3,4. 1. Endocrinology Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. sorina.martin@gmail.com. 2. Endocrinology Department, Elias Hospital, Marasti Avenue 17, 011461, Bucharest, Romania. sorina.martin@gmail.com. 3. Endocrinology Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. 4. Endocrinology Department, Elias Hospital, Marasti Avenue 17, 011461, Bucharest, Romania. 5. Laboratory Department, Elias Hospital, Marasti Avenue 17, 011461, Bucharest, Romania.
Abstract
PURPOSE: We investigated, at diagnosis, the relationship between serum immunoglobulin G4 levels and the main characteristics of Graves' disease: hyperthyroidism severity, goiter size, presence of active Graves' ophthalmopathy, antithyroid antibodies status, and titer. METHODS: This prospective study included 80 newly diagnosed Graves' disease patients. The main parameters measured at diagnosis: thyroid-stimulating hormone, free thyroxine, free triiodothyronine, total triiodothyronine, thyroglobulin, antithyroid peroxidase antibodies, anti-thyroglobulin antibodies, thyroid-stimulating hormone receptor antibodies, immunoglobulin G4. RESULTS: In Graves' disease patients, serum immunoglobulin G4 levels were higher than in general population (p = 0.028) and higher in men compared to women (p = 0.002). Only one female patient with intense hypoechoic goiter, high anti-thyroglobulin antibody, and antithyroid peroxidase antibody titers had an elevated serum immunoglobulin G4 level at diagnosis. Patients with immunoglobulin G4 levels above the 75th percentile (>237.52 mg/dl, N = 20) were younger at Graves' ophthalmopathy onset (p < 0.001), had higher antithyroid peroxidase antibody (p = 0.01), and anti-thyroglobulin antibody levels (p = 0.006) and required shorter duration of the first methimazole treatment cycle (p = 0.041) than patients with immunoglobulin G4 below the 75th percentile. At diagnosis, patients with immunoglobulin G4 levels above the 90th percentile (>286.28 mg/dl, N = 8) had lower total triiodothyronine values (p = 0.001) than patients with IgG below the 90th percentile. No significant correlations were found between smoking status (p = 0.58), goiter size (p = 0.50), the presence of ophthalmopathy (p = 0.42) or thyroid-stimulating hormone receptor antibody titers (p = 0.45) and the mean value of immunoglobulin G4 levels at diagnosis. CONCLUSIONS: Our data suggest that Graves' disease patients with elevated immunoglobulin G4 levels at diagnosis have a phenotype characterized by higher anti-thyroglobulin antibody and antithyroid peroxidase antibody titers, less severe T3 hyperthyroidism, younger age at ophthalmopathy onset and require a shorter duration of the first methimazole treatment cycle.
PURPOSE: We investigated, at diagnosis, the relationship between serum immunoglobulin G4 levels and the main characteristics of Graves' disease: hyperthyroidism severity, goiter size, presence of active Graves' ophthalmopathy, antithyroid antibodies status, and titer. METHODS: This prospective study included 80 newly diagnosed Graves' diseasepatients. The main parameters measured at diagnosis: thyroid-stimulating hormone, free thyroxine, free triiodothyronine, total triiodothyronine, thyroglobulin, antithyroid peroxidase antibodies, anti-thyroglobulin antibodies, thyroid-stimulating hormone receptor antibodies, immunoglobulin G4. RESULTS: In Graves' diseasepatients, serum immunoglobulin G4 levels were higher than in general population (p = 0.028) and higher in men compared to women (p = 0.002). Only one female patient with intense hypoechoic goiter, high anti-thyroglobulin antibody, and antithyroid peroxidase antibody titers had an elevated serum immunoglobulin G4 level at diagnosis. Patients with immunoglobulin G4 levels above the 75th percentile (>237.52 mg/dl, N = 20) were younger at Graves' ophthalmopathy onset (p < 0.001), had higher antithyroid peroxidase antibody (p = 0.01), and anti-thyroglobulin antibody levels (p = 0.006) and required shorter duration of the first methimazole treatment cycle (p = 0.041) than patients with immunoglobulin G4 below the 75th percentile. At diagnosis, patients with immunoglobulin G4 levels above the 90th percentile (>286.28 mg/dl, N = 8) had lower total triiodothyronine values (p = 0.001) than patients with IgG below the 90th percentile. No significant correlations were found between smoking status (p = 0.58), goiter size (p = 0.50), the presence of ophthalmopathy (p = 0.42) or thyroid-stimulating hormone receptor antibody titers (p = 0.45) and the mean value of immunoglobulin G4 levels at diagnosis. CONCLUSIONS: Our data suggest that Graves' diseasepatients with elevated immunoglobulin G4 levels at diagnosis have a phenotype characterized by higher anti-thyroglobulin antibody and antithyroid peroxidase antibody titers, less severe T3 hyperthyroidism, younger age at ophthalmopathy onset and require a shorter duration of the first methimazole treatment cycle.
Authors: Ajay Nirula; Scott M Glaser; Susan L Kalled; Frederick R Taylor; Frederick R Taylora Journal: Curr Opin Rheumatol Date: 2011-01 Impact factor: 5.006
Authors: T Watanabe; M Maruyama; T Ito; Y Fujinaga; Y Ozaki; M Maruyama; R Kodama; T Muraki; H Hamano; N Arakura; M Kadoya; S Suzuki; M Komatsu; H Shimojo; K Notohara; M Uchida; S Kawa Journal: Scand J Rheumatol Date: 2013-03-16 Impact factor: 3.641
Authors: Uwe Schauer; Frank Stemberg; Christian H L Rieger; Michael Borte; Simone Schubert; Frank Riedel; Udo Herz; Harald Renz; Manfred Wick; Hugh D Carr-Smith; Arthur R Bradwell; Wilhelm Herzog Journal: Clin Chem Date: 2003-11 Impact factor: 8.327
Authors: Meihua Jin; Bictdeun Kim; Ahreum Jang; Min Ji Jeon; Young Jun Choi; Yu-Mi Lee; Dong Eun Song; Won Gu Kim Journal: Endocrinol Metab (Seoul) Date: 2022-04-25